To assess dilution and financing risk, first estimate how long a biotech can fund its plans with cash and investments, then determine whether it has actually raised more money or may need to—and what securities or terms could affect existing shareholders. Use the latest Form 10-K and Form 10-Q, then check for later filings. Treat management’s runway estimate and disclosed financing capacity as dated information, not a guarantee that cash will last or that a financing will happen on particular terms.
How long could the company’s cash last?
Start with the latest filings
Read the latest Form 10-K and Form 10-Q together. In each, review management’s discussion of liquidity and capital resources alongside the balance sheet, cash-flow statement, risk factors, and notes on debt, warrants, and equity awards. Relevant details may be spread across those sections. Then check later current reports and prospectus filings for updates or financing completed after the period covered by the quarterly or annual report.
Estimate runway, but do not treat it as a forecast
Start with cash and short-term investments available to fund operations, and compare them with recent operating cash use. A rough historical calculation is liquid resources divided by the average monthly operating cash used over a recent period. This is a starting point, not a reliable prediction of the date cash will run out: trial timing, enrollment, development plans, and other spending can change both the burn rate and the timing of a financing need.
Keep the balance-sheet date attached to every figure. Also distinguish unrestricted cash from restricted cash and other investments: a reported total that includes restricted cash is not necessarily all available for operating expenses. Management’s expected runway is useful context, but check the assumptions behind it and whether later filings have changed them.
#1 Best Overall
Does the company need to raise money, and has it already?
Separate financing access from financing proceeds
A shelf registration or an at-the-market (ATM) program gives an issuer a route or capacity to offer securities; it does not prove that the company sold that amount or received the corresponding cash. Look for reported sales, proceeds, shares issued, fees, and subsequent updates. An ATM may also be less useful when the share price is depressed or markets are volatile.
For example, Spruce Biosciences’ June 2026 quarterly report described a shelf registration of up to $300.0 million and ATM capacity of up to $75.0 million. Those are disclosed capacities, not evidence that Spruce raised either amount. Do not add such capacity to cash on hand or treat it as guaranteed future funding.
Read going-concern language in context
In its Form 10-Q for the quarter ended June 30, 2026, Lipocine stated: “For this reason, there is substantial doubt about our ability to continue as a going concern in the absence of obtaining substantial additional funding.” This is Lipocine’s company-authored disclosure about its own circumstances, not a conclusion about biotech companies generally. Read the surrounding discussion to understand the stated cause, possible funding routes, and risks.
What could dilute existing shareholders?
Count issued shares and potential shares
Do not stop at common shares currently outstanding. Check for common shares issued in recent financings and potential shares from warrants, pre-funded warrants, options, equity awards, and convertible securities. For each, review the number of shares or conversion amount, exercise or conversion price, expiration, restrictions, and any preferences or other rights. Some instruments may be conditional or may never become common shares, so distinguish currently issued shares from potential shares rather than treating every potential share as certain.
Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Repair Windows errors before they cause bigger problems3Fix the driver behind crashes, sound loss and screen glitchesLipocine’s June 2026 report described a May 2026 registered direct offering of 1,454,175 common shares and pre-funded warrants for up to 681,748 shares, along with additional warrants in a concurrent private placement. The filing illustrates why the headline count of common shares sold may not capture all potential shares or financing terms. Use the filing’s complete terms to determine what the warrants could add and under what conditions.
Compare dilution with what the company received
For a completed financing, compare cash proceeds with the number and type of securities issued, including potential shares. Consider the offering price and warrant or conversion terms, but do not assume the quoted gross amount equals cash available for operations: check reported net proceeds and any associated fees or obligations. A financing can also affect common shareholders through senior rights, preferences, or debt covenants, even if the immediate share-count change is modest.
Rank #4
How should you compare possible funding routes?
When a company has more than one plausible funding route, compare each on the same dimensions. A collaboration, grant, licensing deal, or other non-equity source may reduce the need for a share issuance, but regard it as a possibility until the company reports an executed and funded arrangement.
- Cash and timing: How much funding is expected, when could it arrive, and is it committed or conditional?
- Share impact: How many new shares could be issued, including warrant, pre-funded warrant, or conversion shares? Compare both issued shares and a fully diluted view, while noting which potential securities are conditional.
- Price and rights: What are the offering, exercise, or conversion prices? Are there warrants, preferences, or other rights that change the economics for common shareholders?
- Debt terms: Does borrowing introduce repayment obligations or covenants that could constrain the company?
- Execution uncertainty: Is the route an available mechanism, a proposed transaction, or a completed and funded deal? Could market conditions or other requirements prevent it from delivering the expected cash?
The issuer examples below show why the categories should not be confused; they are company-specific disclosures, not sector benchmarks or a like-for-like comparison of financing choices.
Free tools Windows power users keep installed
One-click scans. No signup required.
| Issuer and filing | Reported item | How to interpret it |
|---|---|---|
| aTyr Pharma, March 31, 2026 balance reported in 2026 | $68.3 million in cash, cash equivalents, restricted cash, and available-for-sale investments | A dated balance for one issuer. Because the total includes restricted cash and investments, it should not automatically be treated as entirely unrestricted operating cash. |
| Spruce Biosciences, June 2026 quarterly report | Up to $300.0 million under a shelf registration and ATM offering capacity of up to $75.0 million | Disclosed offering capacities, not evidence that the company sold securities or raised those amounts. |
| Lipocine, June 2026 report describing its May 2026 offering | 1,454,175 common shares and pre-funded warrants for up to 681,748 shares in a registered direct offering, plus additional warrants in a concurrent private placement | A completed share offering can have further potential share effects through warrants; examine the full transaction terms. |
What should you verify before relying on an estimate?
- Record the date and composition of the reported cash and investments; identify amounts that are restricted or otherwise unavailable for operations.
- Find operating cash use and the planned clinical or development spending that informs management’s runway estimate.
- Check when management expects cash to last and which trial, enrollment, or development assumptions could move that estimate.
- Separate financing capacity from actual sales, proceeds, and shares issued; look for updates after the periodic report.
- Inventory outstanding and potential shares, including warrants, pre-funded warrants, options, awards, and convertible securities, and read their terms.
- For each plausible funding route, weigh proceeds and timing against share count, pricing, seniority, covenants, and execution uncertainty.
All company figures and disclosures above are from specific issuer reports in 2026. They do not establish typical biotech runway, typical financing amounts, or what any issuer will raise in the future. Cash balances, financing capacity, warrant terms, and runway can change; refresh the analysis with later filings before relying on it.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
